AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate...

AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to
Educate Physicians and Consumers on Risks Associated With NSAID Use

- Webinar on June 9 to discuss the prevalence and prevention of NSAID-induced
ulcers available at www.connecttoprotect.com-

BETHESDA, Md. and CHICAGO, June 1 /PRNewswire/ -- The American
Gastroenterological Association (AGA) Institute and Horizon Therapeutics, Inc.
today launched Connect to Protect, a program to increase awareness about the
gastrointestinal (GI) risks associated with the use of non-steroidal
anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen. Connect to
Protect was created to highlight the connection between NSAID use and GI
risks, and to encourage patients and physicians to connect more often about
ways to avoid NSAID-induced ulcers, including but not limited to GI protective
co-therapy.

"NSAIDs are among the most widely prescribed classes of drugs in the world,
yet there is still very limited discussion among healthcare providers and
their patients about the impact long-term use could have," said Byron Cryer,
MD, professor, Internal Medicine - Digestive and Liver Diseases, University of
Texas Southwestern, and independent medical advisor, Connect to Protect
program. "The goal of Connect to Protect is to facilitate the discussion
between physicians and patients around the potential risks in taking chronic
NSAIDs and to understand how to reduce a patient's risk."

Connect to Protect will sponsor an educational Webinar hosted by Dr. Cryer on
Tuesday, June 9, 2009 from 12 p.m. to 1 p.m. EDT, during which he will discuss
the prevalence of NSAID-induced ulcers, the causes and ways to reduce the
risk. The Webinar is open to healthcare providers and media. To register in
advance, please visit: www.connecttoprotect.com.

"We are excited to partner with the AGA Institute on this important
initiative," said Timothy P. Walbert, president and chief executive officer,
Horizon Therapeutics. "For many physicians and their patients,
NSAID-associated GI ulcers are rarely discussed, and when they are it is often
too late. Connect to Protect is an important step to increase awareness of
the problem and provide education and resources to address it."

About NSAIDs and GI Toxicity
It is estimated that more than 60 million Americans use NSAIDs regularly,
resulting in clinically significant upper GI events in one to two percent of
users. NSAIDs, most often used for the treatment of arthritis and pain, block
enzymes and reduce prostaglandins throughout the body and as a consequence,
ongoing inflammation, pain and fever are reduced. Since the prostaglandins
that protect the stomach are reduced, NSAIDs often cause ulcers in the
stomach. It is estimated that GI hemorrhages due to NSAID use account for
approximately 60,000-120,000 hospital admissions annually. Though difficult
to quantify, available reports suggest that deaths from NSAID-related GI
events vary from 3,200 to more than 16,500 per year in the United States.

For more information on the risks of chronic NSAID use and ways to avoid or
reduce those risks, please visit www.connecttoprotect.com. In addition to
facts on the risks of NSAID use, there are discussion guides for physicians
and their patients about avoiding or reducing risks associated with chronic
NSAIDs.

About the AGA Institute
The American Gastroenterological Association (AGA) is dedicated to the mission
of advancing the science and practice of gastroenterology. Founded in 1897,
the AGA is one of the oldest medical-specialty societies in the U.S. Comprised
of two non-profit organizations -- the AGA and the AGA Institute -- our more
than 17,000 members include physicians and scientists who research, diagnose
and treat disorders of the gastrointestinal tract and liver. The AGA
administers all membership and public policy activities, while the AGA
Institute runs the organization's practice, research and educational programs.
On a monthly basis, the AGA Institute publishes two highly respected journals,
Gastroenterology and Clinical Gastroenterology and Hepatology. The
organization's annual meeting is Digestive Disease Week(R), which is held each
May, is the largest international gathering of physicians, researchers and
academics in the fields of gastroenterology, hepatology, endoscopy and
gastrointestinal surgery. For more information, please visit www.gastro.org.

About Horizon Therapeutics
Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused
on the development and commercialization of therapies for the treatment of
mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes
innovative combination therapies in early- and late-stage development that are
designed to improve safety, efficacy and patient compliance. For more
information about the company and its products, please visit
www.horizontherapeutics.com.

Funding for the program was provided through a grant from Horizon
Therapeutics.

SOURCE Horizon Therapeutics, Inc.

Dianne Bach of AGA Institute, +1-301-941-2623, dbach@gastro.org; or Molly
Rabinovitz of WeissComm Partners, +1-312-646-6294, mrabinovitz@wcpglobal.com,
for Horizon Therapeutics, Inc.